Echo Therapeutics, Inc. (ECTE)
-NasdaqCM 0.50 
0.02(3.96%) 10:24AM EDT - Nasdaq Real Time Price
| Prev Close: | 0.48 |
|---|
| Open: | 0.50 |
|---|
| Bid: | 0.50 x 1100 |
|---|
| Ask: | 0.51 x 200 |
|---|
| 1y Target Est: | 2.92 |
|---|
| Beta: | 1.18 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 0.47 - 0.51 |
|---|
| 52wk Range: | 0.18 - 2.00 |
|---|
| Volume: | 46,475 |
|---|
| Avg Vol (3m): | 226,759 |
|---|
| Market Cap: | 26.93M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Echo Therapeutics announces Institutional Review Board approval for its clinical trial of the Symphony CGM SystemBriefing.com(Tue, May 21)
- Echo Therapeutics Announces Institutional Review Board (IRB) Approval for Its Clinical Trial of the Symphony® CGM SystemPR Newswire(Tue, May 21)
- ECHO THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Dario Seeks To Capitalize On New Technology For Diabetic Test Stripsat Seeking Alpha(Thu, May 16)
- Echo Therapeutics to Unveil Symphony® CGM System in WebcastPR Newswire(Thu, May 16)
- LabStyle Innovations - Glucose Monitoring For The Mobile Ageat Seeking Alpha(Wed, May 15)
- ECHO THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EEDGAR Online(Fri, May 10)
- ECHO THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Echo Therapeutics Announces First Quarter 2013 Financial ResultsPR Newswire(Fri, May 10)
- Hedge Fund Platinum Partners’ Favorite Stocks Might Surprise Youat Motley Fool(Tue, Apr 30)
- ECHO THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Notice of Delisting or FaiEDGAR Online(Fri, Mar 22)
- Echo Therapeutics, Inc. Announces 2012 Financial ResultsPR Newswire(Mon, Mar 18)
- ECHO THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibEDGAR Online(Mon, Mar 18)
- Echo Therapeutics Achieves ISO 13485 CertificationPR Newswire(Fri, Mar 15)
- 4 Healthcare Stock Stories for Wednesday Investment Wellnessat Wall St. Cheat Sheet(Wed, Mar 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.36 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -0.03 |
|---|
Business Summary
Echo Therapeutics, Inc. operates as a transdermal medical device company in the United States. The company is involved in developing Prelude SkinPrep System, which is a platform technology to allow painless skin permeation that would enable both n...
View More